2 studies on Glucagon agonist mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides compelling evidence that Retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, offers direct and indirect benefits for kidney health in individuals with Type 2 Diabetes …